Dec 24 (Reuters) - Telix Pharmaceuticals Ltd TLX.AX :
* SUBMITTED PHASE 3 INVESTIGATIONAL NEW DRUG APPLICATION TO U.S. FDA FOR TLX250-CDX (89ZR-GIRENTUXIMAB)
Dec 24 (Reuters) - Telix Pharmaceuticals Ltd TLX.AX :
* SUBMITTED PHASE 3 INVESTIGATIONAL NEW DRUG APPLICATION TO U.S. FDA FOR TLX250-CDX (89ZR-GIRENTUXIMAB)